The estimated Net Worth of W Thorpe Mckenzie is at least $27.1 Million dollars as of 16 December 2021. Mr. Mckenzie owns over 250,000 units of XBiotech Inc stock worth over $18,186,937 and over the last 9 years he sold XBIT stock worth over $8,795,003. In addition, he makes $137,000 as Independent Director at XBiotech Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr. McKenzie XBIT stock SEC Form 4 insiders trading
W has made over 17 trades of the XBiotech Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 250,000 units of XBIT stock worth $2,500,000 on 16 December 2021.
The largest trade he's ever made was selling 385,000 units of XBiotech Inc stock on 4 October 2018 worth over $1,155,000. On average, W trades about 52,907 units every 68 days since 2015. As of 16 December 2021 he still owns at least 2,810,964 units of XBiotech Inc stock.
You can see the complete history of Mr. Mckenzie stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
W. Thorpe McKenzie biography
W. Thorpe Jerome McKenzie serves as Independent Director of the Company. Mr. McKenzie served as Managing Director of Pointer Management Company, Chattanooga, Tennessee, since its inception in July 1990 until December 31, 2015, and as of January 1, 2016, serves as its Senior Advisor. Mr. McKenzie co-founded Pointer Management Company in July 1990 to invest in hedge funds and similar types of partnerships utilizing a fund of funds approach. From August 1982 until June 1990, he was a private investor in New York City, and a director of several public and private companies. From May 1980 until July 1982, he was founding general partner at TIGER, a global hedge fund. From May 1971 until January 1980, he was a Vice President of Kidder, Peabody & Co., Inc. in New York. Mr. McKenzie is a graduate of the University of North Carolina in Chapel Hill and the Wharton Graduate division of the University of Pennsylvania in Philadelphia.
What is the salary of W McKenzie?
As the Independent Director of XBiotech Inc, the total compensation of W McKenzie at XBiotech Inc is $137,000. There are 6 executives at XBiotech Inc getting paid more, with John Simard having the highest compensation of $10,810,400.
How old is W McKenzie?
W McKenzie is 72, he's been the Independent Director of XBiotech Inc since 2018. There are 1 older and 8 younger executives at XBiotech Inc. The oldest executive at XBiotech Inc is Peter Libby, 73, who is the Independent Director.
What's W McKenzie's mailing address?
W's mailing address filed with the SEC is 832 GEORGIA AVENUE, SUITE 1100, CHATTANOOGA, TN, 37402.
Insiders trading at XBiotech Inc
Over the last 9 years, insiders at XBiotech Inc have traded over $50,443,920 worth of XBiotech Inc stock and bought 1,428,502 units worth $11,921,113 . The most active insiders traders include Street Financial S.A. Bay, Fondation Rennes, and W Thorpe Mckenzie. On average, XBiotech Inc executives and independent directors trade stock every 48 days with the average trade being worth of $1,053,782. The most recent stock trade was executed by W Thorpe Mckenzie on 16 December 2021, trading 250,000 units of XBIT stock currently worth $2,500,000.
What does XBiotech Inc do?
xbiotech is developing a first-in-class monoclonal antibody (mabp1) to inhibit chronic inflammation. chronic (sterile) inflammatory responses are involved in the progression of many serious and common diseases. mabp1 is being investigated in many important areas of medicine, including: cancer, leukemia (phase 1); type 2 diabetes (phase2); psoriasis (phase 2); and vascular disease (phase 2). mabp1 is a true human™ antibody cloned from a natural human immune response and—unlike currently marketed antibodies—it has not undergone any modification to alter its function. it has exhibited the best potential tolerability and safety during the clinical trials. xbiotech has established a current good manufacturing practices (cgmp) program to commercialize its lead product candidate. the company has purchased land and designed a commercial-scale plant with 25,000l total bioreactor capacity. construction of the facility is planned to commence in 4th quarter 2011..
What does XBiotech Inc's logo look like?
Complete history of Mr. Mckenzie stock trades at XBiotech Inc
XBiotech Inc executives and stock owners
XBiotech Inc executives and other stock owners filed with the SEC include:
-
John Simard,
Chairman of the Board, President, Chief Executive Officer, Founder -
John Simard,
Founder, Pres, CEO & Chairman -
Sushma Shivaswamy,
Chief Scientific Officer -
Queena Han,
Vice President - Finance and Human Resources, Secretary -
Dr. Sushma Shivaswamy,
Chief Scientific Officer -
Queena Han CPA, B.A., CPA, C.G.A.,
VP of Fin. & HR and Sec. -
W. Thorpe McKenzie,
Independent Director -
Donald MacAdam,
Independent Director -
Peter Libby,
Independent Director -
Jan-Paul Waldin,
Lead Independent Director -
Lisa Simard,
Director of Corp. Strategy - XBiotech USA, Inc. -
BenjamÃn Guzmán,
Sr. VP of Corp. Strategy & Fin. -
Daniel Vasella,
Director -
Trey Benson,
VP of Commercial Development -
Kelly Thornburg,
SVP of Operations -
Fabrizio Bonanni,
Director -
Dawn Mc Collough,
VP Clinical Operations -
Michael Stecher,
Medical Director -
Kalidip Choudhury,
VP of Business Development -
James Scott Whitehurst,
Chief Financial Officer -
Thomas Gut,
10% owner -
Benjamin Guzman,
Sr.VP Corp. Strategy & Finance -
Fondation Rennes,
10% owner -
Street Financial S.A. Bay,
10% owner